Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system; vCLAS ventricular ULTC catheter; and Cryopulse pulsed field cryoablation catheters. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.…
Adagio Medical Reports Third Quarter 2026 Results
Adagio Medical Holdings (NASDAQ: ADGM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 41 employees.
The shares were at 1.750 USD on 20 November 2026, down 93.2% over 52 weeks. Its 52-week range is 1.450 USD to 50.70 USD: the price is 96.5% below the high and 20.7% above the low.
Its market capitalisation is 1.72M USD.
Adagio Medical Holdings reports return on equity of -202.3% and an operating margin of 0.0%.
Its debt exceeds its cash by 18.26M USD, a debt-to-equity ratio of 1.75. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.